Viking Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Viking Therapeutics has a total shareholder equity of $911.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $937.9M and $26.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$930.44m |
| Equity | US$911.45m |
| Total liabilities | US$26.44m |
| Total assets | US$937.89m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0VQA's short term assets ($936.6M) exceed its short term liabilities ($25.7M).
Long Term Liabilities: 0VQA's short term assets ($936.6M) exceed its long term liabilities ($755.0K).
Debt to Equity History and Analysis
Debt Level: 0VQA is debt free.
Reducing Debt: 0VQA had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0VQA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 0VQA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 25% each year